SL PHARM: Downgraded performance expectations，预计 losses of 73 million to 95 million yuan in 2024

SL PHARM released a revised performance forecast announcement for the year 2024, expecting a loss of 73 million to 95 million yuan, compared to the previous estimate of a loss of 32 million to 52 million yuan for 2024. The reason for the performance revision: As the preparation work for the company's 2024 annual report deepens and the further collection and consolidation of data from various subsidiaries progresses, it was found that the offsetting of certain items between the parent and subsidiary companies in the performance forecast was insufficient, resulting in discrepancies between the previous performance forecast data and the actual situation